Mr. Watkins graduated from William & Mary with a BBA in Accounting; he earned his MBA in 1979 from the University of Chicago Graduate School of Business. Mr. Watkins most recently served as President and CEO of Human Genome Sciences until that company was acquired by GlaxoSmithKline in 2012. His previous business experience is with Abbott, TAP Pharmaceuticals (jointly owned by Abbott and Takeda Pharmaceutical Company), McKinsey & Co., and Arthur Andersen & Co. Mr. Watkins is currently Chair of the Board of Directors of Vanda Pharmaceuticals, Inc., and a member of the boards of Horizon Pharma, plc., the Biotechnology Industry Organization (BIO), and the Ann and Robert H. Lurie Foundation. Mr. Watkins is a past chair of the William & Mary Foundation. His father, Hays Watkins Jr., was a member of the Board of Visitors from 1984 to1993 and served as Rector from 1987 to 1993; his daughter, Catherine, and son, Hays T. Watkins IV, are both graduates of William & Mary. Mr. Watkins was appointed to the Board of Visitors in 2013 and reappointed in 2017. Previously, he served as Vice Rector of the College (2015-2018), Chair of the Presidential Search Committee for the 28th President of William & Mary (2017-2018) and Chair of the Committee on Financial Affairs. Currently, he serves as Chair of the Committee on the Student Experience, and is a member of the Committee on Institutional Advancement and the Committee on Financial Affairs, where he is Vice Chair of its Investments Subcommittee.